secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001619856-24-000068
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Biosciences appoints Tina Albertson, MD PhD, as Chief Medical Officer
-----------------------------------------------------------------------------

- Dr. Albertson brings 15 years of experience in cellular therapy development, most recently as CMO at Lyell Immunopharma.
- At Juno Therapeutics (BMS), she led global development of BREYANZI from IND to BLA filing and FDA approval.
- She will oversee clinical, regulatory, and medical affairs for Caribou's four CAR-T cell therapy programs.
- Dr. Albertson reports to CEO Rachel Haurwitz and will drive allogeneic CAR-T development in hematologic and autoimmune diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985624000068/0001619856-24-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985624000068/crbu-20240812.htm
  HTML page:      https://secwatch.observer/filing/0001619856-24-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer